Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy

2012 ◽  
Author(s):  
Higmar Herrera ◽  
Elvia Yañez ◽  
Jesús López
Keyword(s):  
Uterine Cervix ◽  
Concurrent Chemotherapy ◽  
Cervix Cancer ◽  
Uterine Cervix Cancer

Computed tomography of iliopsoas involvement in uterine cervix cancer

1987 ◽  
Vol 23 (6) ◽  
pp. 1038
Author(s):  
J U Chung ◽  
B I Choi ◽  
S H Kim ◽  
M C Han ◽  
C W Kim
Keyword(s):  
Computed Tomography ◽  
Uterine Cervix ◽  
Cervix Cancer ◽  
Uterine Cervix Cancer

Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1

2004 ◽  
Vol 93 (1) ◽  
pp. 182-188 ◽  
Author(s):  
Emmanuel Contassot ◽  
Mirna Tenan ◽  
Valérie Schnüriger ◽  
Marie-Françoise Pelte ◽  
Pierre-Yves Dietrich
Keyword(s):  
Cancer Cells ◽  
Uterine Cervix ◽  
Vanilloid Receptor ◽  
Cervix Cancer ◽  
Uterine Cervix Cancer ◽  
Vanilloid Receptor 1

Depression before and after uterine cervix and breast cancer neoadjuvant chemotherapy

2002 ◽  
Vol 12 (6) ◽  
pp. 773-776 ◽  
Author(s):  
C. R. R. Miranda ◽  
C. N. De Resende ◽  
C. F. E. Melo ◽  
A. L. Costa ◽  
H. Friedman
Keyword(s):  
Breast Cancer ◽  
Treatment Outcome ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Uterine Cervix ◽  
Cervix Cancer ◽  
Breast Cancer Patients ◽  
Uterine Cervix Cancer ◽  
End Of Treatment ◽  
Before And After

Depression in cancer patients is common and may affect treatment outcome either directly (by lowering defenses) or indirectly (by lowering compliance). Neoadjuvant chemotherapy for advanced uterine cervix or breast cancer is a strenuous undertaking and may lead to depression and impair patients' willingness to comply with the rest of the treatment (eg, surgery or radiotherapy).We compare Beck Depression Inventory (BDI) scores both before and after neoadjuvant chemotherapy in order to verify if depression influences treatment outcome. We studied 22 advanced uterine cervix and 20 breast cancer patients submitted to three courses of neoadjuvant chemotherapy. We used cisplatin and ifosfamide for cervix, and fluorouracil, adriamycin, and cyclophosphamide for breast cancer. We did not identify significant differences in the number of depressed patients, before and after treatment. Cognitive affective, somatic-performance, and total BDI scores were not significantly different from before to after chemotherapy for both breast and uterine cervix cancer. After treatment, the number of depressive breast cancer patients increased while the number of uterine cervix cancer patients decreased. This trend to depression was found more often in less responsive breast cancer patients than in the more responsive cervix cancer patients. We were not able to link depression to treatment failure or success, but patients who responded to treatment were less depressed at the end of treatment.

Sign in / Sign up

Export Citation Format

Share Document